December 1, 2025 — PharmaCorp Rx Inc. (TSXV: PCRX) announced an executive transition where Paul Dale was appointed President and Chief Operating Officer, effective December 1, 2025. Calvin LeRoux will transition from his role as President to Strategic Advisor to the Chief Executive Officer for one year.
Paul Dale, previously PharmaCorp’s Chief Operating Officer since its beginning, will assume increased leadership duties as the company progresses with its national expansion strategy.
Alan Simpson, Executive Chairman of PharmaCorp, stated that Dale’s appointment reinforces the continuity of their operating model and demonstrates their confidence in his leadership. He added that Dale’s experience in managing complex retail organizations and his consistent performance during acquisition and integration efforts make him exceptionally suited for this expanded role.
Calvin LeRoux’s term as President will end on November 30, 2025. As Strategic Advisor, he will support the transition of responsibilities, contribute to strategic initiatives, and continue to advise on matters related to PharmaChoice Canada.
Simpson noted LeRoux’s significant role in PharmaCorp’s early development and in strengthening their relationship with PharmaChoice Canada. He expressed pleasure that LeRoux will continue to support PharmaCorp in an advisory capacity.
PharmaCorp also announced the appointment of Sophia Sigler as Director of Business Development, effective December 1, 2025. Sigler will spearhead PharmaCorp’s business development efforts, including identifying acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and assisting pharmacist partners with co-ownership and succession structures.
PharmaCorp Rx Inc. is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. By combining capital, strategic support, and operational expertise, PharmaCorp aims to create a national network of community pharmacies under the PharmaChoice Canada banner. Currently, PharmaCorp operates seven pharmacies bannered as PharmaChoice Canada and will continue to acquire both PharmaChoice Canada bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform, consistent with its strategic alliance with PharmaChoice Canada.
PharmaCorp welcomes discussions with pharmacy owners considering succession or sale. Further details regarding their acquisition program and process can be found at www.PharmaCorpRx.ca. The company ensures seamless transitions that protect legacies and serve communities.
Investor Relations can be contacted at info@pharmacorprx.ca or by telephone at (306) 536-3771.
Source: PharmaCorp Rx Inc.
